CYTH - Cyclo Therapeutics, Inc. Stock Price, Fair Value and News

$0.68-0.04 (-5.56%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CYTH Price Action

Last 7 days

-5.4%

Last 30 days

-11.4%

Last 90 days

-44.4%

Trailing 12 Months

-48.5%

CYTH RSI Chart

CYTH Valuation

Market Cap

19.6M

Price/Earnings (Trailing)

-0.79

Price/Sales (Trailing)

8.54

EV/EBITDA

-0.75

Price/Free Cashflow

-0.87

CYTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CYTH Fundamentals

CYTH Revenue

Revenue (TTM)

2.3M

Rev. Growth (Yr)

-52.82%

Rev. Growth (Qtr)

-58.35%

CYTH Earnings

Earnings (TTM)

-24.8M

Earnings Growth (Yr)

-85.12%

Earnings Growth (Qtr)

-47.68%

CYTH Profitability

EBT Margin

-1082.78%

Return on Equity

184.06%

Return on Assets

-472.02%

Free Cashflow Yield

-115.11%

CYTH Investor Care

Shares Dilution (1Y)

26.55%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.4M	2.6M	2.3M	0
2023	2.8M	2.5M	2.6M	2.3M
2022	1.4M	1.7M	1.7M	2.5M
2021	1.0M	1.2M	1.6M	1.5M
2020	1.1M	1.0M	835.0K	989.6K
2019	1.0M	957.9K	1.0M	1.0M
2018	1.1M	957.1K	940.4K	1.0M
2017	1.5M	1.6M	1.6M	1.2M
2016	1.1M	1.1M	1.1M	1.5M
2015	1.2M	1.4M	1.2M	950.5K
2014	1.7M	1.1M	1.4M	1.6M
2013	1.2M	1.7M	1.8M	1.7M
2012	1.2M	941.3K	867.4K	988.0K
2011	853.0K	912.6K	972.2K	1.0M
2010	0	0	0	793.4K

Get all data in R, Python etc through our Historical Stock Data APIs

About Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

CEO	Mr. N. Scott Fine
WEBSITE	https://cyclotherapeutics.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	9

Cyclo Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Cyclo Therapeutics, Inc.? What does CYTH stand for in stocks?

CYTH is the stock ticker symbol of Cyclo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyclo Therapeutics, Inc. (CYTH)?

As of Tue Nov 19 2024, market cap of Cyclo Therapeutics, Inc. is 19.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYTH stock?

You can check CYTH's fair value in chart for subscribers.

Is Cyclo Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CYTH is over valued or under valued. Whether Cyclo Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cyclo Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYTH.

What is Cyclo Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 19 2024, CYTH's PE ratio (Price to Earnings) is -0.79 and Price to Sales (PS) ratio is 8.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cyclo Therapeutics, Inc.'s stock?

In the past 10 years, Cyclo Therapeutics, Inc. has provided -0.367 (multiply by 100 for percentage) rate of return.